beta

GRTS

Gritstone Bio Inc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

gritstone oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. the company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer. gritstone oncology is headquartered in the san francisco bay area with certain key functions located in cambridge, ma. gritstone oncology launched in october 2015 with a series a financing of $102 million.

Market Cap: 214 Million

Primary Exchange: NASDAQ

Website: https://gritstoneoncology.com/

Shares Outstanding: 98.1 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.5517947670862824

Sector: Manufacturing

Industry: Biological Product (except Diagnostic) Manufacturing

Ethical Flags

Longest drawdown: 1579 trading days

From: 2018-12-06 To: 2024-03-07

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud